Biomarkers: Shaking Up--and Protecting--the World's Biggest Drug Market
Executive Summary
The ASTEROID trial for Crestor, showing that it's the first statin known to reduce arterial plaque, has shaken up the $20 billion statin business, showing how biomarkers-not clinical endpoints-can dramatically shift share in even well established markets. And while the news was largely bad for beleaguered Lipitor, the trial's reaffirmation of the importance of potency also shows why the coming generics won't significantly hurt the market leaders.
You may also be interested in...
Pfizer's Analyst Day: And Now, For Its Next Trick
Pfizer was vague in describing to analysts just how it would reduce costs by $4 billion per year by 2008. The FDA's announcement that it had asked Pfizer to remove the Cox-2 inhibitor Bextra from the market just days later complicates matters for the pharmaceutical giant. In any case, those hoping for a significant headcount reduction among Pfizer sales reps were surely disappointed.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
EU Must Crack Down Harder On Fake Medical Devices, Says Innovator
Counterfeit copies of LifeVac Europe’s anti-choking devices have been registered on the EU’s EUDAMED database and continue to be sold on third-party platforms. Medtech Insight asked director of sales and marketing Matthew Banagan how the company deals with fake devices and what the authorities must do.